| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*
Laboratoire d’Immunologie Cellulaire and
Unité d’Immunothérapie, Institut Gustave-Roussy, Cedex, France
We performed T cell cloning experiments with a tumor-infiltrating lymphocyte subpopulation derived from a renal cell carcinoma tumor site (RCC-7) in which the TCR clonotypic repertoire had been analyzed in terms of TCRBV complementarity-determining region 3 size distribution. We report in this work the characterization of one of the five RCC-specific MHC class I-restricted CTL clones isolated in RCC-7. This TCRBV6J1S1 CTL recognized only the autologous RCC-7 tumor cell line in the context of HLA-A*0201, and the Ag is encoded by a mutated form of the hsp70-2 gene found in the tumor cells, but not in autologous PBLs nor in 47 other tumors. The identification of this gene was achieved by cotransfecting into COS cells a cDNA library of RCC-7 together with HLA-A*0201. Transfectants expressing the Ag were identified by their ability to stimulate TNF release by the CTL clone. The antigenic peptide is a decamer with a mutated residue at position 8. Half-maximal lysis was obtained with only 5 x 10-11 M of decapeptide in target sensitization assays compared with 5 x 10-8 M for the wild-type decapeptide. This difference in recognition was not related to difference in binding HLA-A*0201-presenting molecules, as assessed in an immunofluorescence-based peptide-binding assay using T2 cells. Constitutive hsp70 expression in various tumors suggests that this stress-induced protein may be recognized in situ by tumor-infiltrating lymphocytes. The finding in the tumor of a mutated form of the stress-induced hsp70-2 gene whose product is specifically recognized by TILs with high avidity is discussed in view of the present use of mycobacteria or heterologous heat-shock proteins as immunomodulators or as subunit vaccine candidates.
This article has been cited by other articles:
|
|
 |
|
  G. Parmiani, A. De Filippo, L. Novellino, and C. Castelli Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials J. Immunol., February 15, 2007; 178(4): 1975 - 1979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kausche, T. Wehler, E. Schnurer, V. Lennerz, W. Brenner, S. Melchior, M. Grone, M. Nonn, S. Strand, R. Meyer, et al. Superior Antitumor In vitro Responses of Allogeneic Matched Sibling Compared with Autologous Patient CD8+ T Cells Cancer Res., December 1, 2006; 66(23): 11447 - 11454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sensi and A. Anichini Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy Clin. Cancer Res., September 1, 2006; 12(17): 5023 - 5032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tassi, V. Facchinetti, S. Seresini, A. Borri, G. Dell'Antonio, C. Garavaglia, G. Casorati, and M. P. Protti Peptidome from Renal Cell Carcinoma Contains Antigens Recognized by CD4+ T Cells and Shared among Tumors of Different Histology. Clin. Cancer Res., August 15, 2006; 12(16): 4949 - 4957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhou, D. Y. Jun, A. M. Thomas, X. Huang, L.-Q. Huang, J. Mautner, W. Mo, P. F. Robbins, D. M. Pardoll, and E. M. Jaffee Diverse CD8+ T-Cell Responses to Renal Cell Carcinoma Antigens in Patients Treated with an Autologous Granulocyte-Macrophage Colony-Stimulating Factor Gene-Transduced Renal Tumor Cell Vaccine Cancer Res., February 1, 2005; 65(3): 1079 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Tykodi, E. H. Warren, J. A. Thompson, S. R. Riddell, R. W. Childs, B. E. Otterud, M. F. Leppert, R. Storb, and B. M. Sandmaier Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning: Toxicity, Clinical Response, and Immunological Response to Minor Histocompatibility Antigens Clin. Cancer Res., December 1, 2004; 10(23): 7799 - 7811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Hanada, D. M. Perry-Lalley, G. A. Ohnmacht, M. P. Bettinotti, and J. C. Yang Identification of Fibroblast Growth Factor-5 as an Overexpressed Antigen in Multiple Human Adenocarcinomas Cancer Res., July 1, 2001; 61(14): 5511 - 5516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Guerra, M. Guillard, E. Angevin, H. Echchakir, B. Escudier, A. Moretta, S. Chouaib, and A. Caignard Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas Blood, May 1, 2000; 95(9): 2883 - 2889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Van den Eynde, B. Gaugler, M. Probst-Kepper, L. Michaux, O. Devuyst, F. Lorge, P. Weynants, and T. Boon A New Antigen Recognized by Cytolytic T Lymphocytes on a Human Kidney Tumor Results from Reverse Strand Transcription J. Exp. Med., December 20, 1999; 190(12): 1793 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hannier and F. Triebel The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes Int. Immunol., November 1, 1999; 11(11): 1745 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Suzuki, H. Sahara, Y. Okada, T. Yasoshima, Y. Hirohashi, Y. Nabeta, I. Hirai, T. Torigoe, S. Takahashi, A. Matsuura, et al. Identification of Natural Antigenic Peptides of a Human Gastric Signet Ring Cell Carcinoma Recognized by HLA-A31-Restricted Cytotoxic T Lymphocytes J. Immunol., September 1, 1999; 163(5): 2783 - 2791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ronsin, V. Chung-Scott, I. Poullion, N. Aknouche, C. Gaudin, and F. Triebel A Non-AUG-Defined Alternative Open Reading Frame of the Intestinal Carboxyl Esterase mRNA Generates an Epitope Recognized by Renal Cell Carcinoma-Reactive Tumor-Infiltrating Lymphocytes In Situ J. Immunol., July 1, 1999; 163(1): 483 - 490. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
